Doctors are failing to lower heart patients' cholesterol adequately
March 10, 2010Only half of all patients at high risk of heart disease are given correct targets for lowering their cholesterol levels according to a study of 25,250 patients in Germany published online today in the European Heart Journal.
The study investigated the way primary care doctors assessed their patients' risk factors and other health problems when deciding on cholesterol-lowering targets, and although the research focused on German doctors and their patients, the authors believe that it reflects a similar picture in the rest of Europe. They say that approximately 50-80 fewer heart attacks, strokes and heart disease-related deaths per 1000 patients over a 10-year period could be avoided if all doctors followed the example of the best doctors who adhered to the guidelines on cholesterol-lowering targets.
Cholesterol is a fatty substance known as a lipid and it is carried in the blood on proteins called low-density lipoproteins (LDL). Having high cholesterol levels (hyperlipidaemia) is a major risk factor for the development of blocked arteries (atherosclerosis) and heart disease, and, therefore, lowering cholesterol via drugs, diet and other lifestyle measures, is an important preventative measure.
The researchers found that in a survey of 907 doctors, involving 25,250 patients, just over half of male patients (55%) and less than half (49%) of female patients were assigned correct LDL targets. Patients were more likely to be given correct targets if they had a history of heart attacks, coronary artery disease, with or without bypass surgery, and diabetes. However, doctors were more likely to underestimate women's risk and assign them incorrect targets. For instance, despite an identical history with a recent heart attack, nearly 68% of men and only 60% of women were given correct treatment targets for LDL lowering.
Professor Heribert Schunkert, who led the research, said that if more doctors followed existing guidelines on cholesterol-lowering targets they could prevent a greater number of heart disease-related incidents such as heart attacks, strokes and deaths.
"We know already that statin therapy can reduce the 10-year incidence of major coronary events by about 30-40 percent per 40 mg/dl [milligrams per decilitre] reduction in LDL cholesterol. In our study we observed an average difference in LDL target levels of just over 17 mg/dl between physicians with the least and best guideline knowledge, and this difference will certainly lead to a sizeable difference in major heart-related problems. In the high risk patients in our study, such a difference in LDL cholesterol translates into approximately 13-17 percent fewer events, or, in a rough calculation, about 50 to 80 fewer heart attacks, strokes and cardiovascular deaths per 1000 patients in 10 years in the group of patients treated by the best physicians who are adhering to the guidelines on cholesterol-lowering targets. While this may be a rough estimate, the numbers highlight the enormous health implications reflected in our findings," said Prof Schunkert, who is a clinical cardiologist and head of the Medizinische Klinik II (medical clinic II) at the Universitätsklinik Schleswig Holstein, Lübeck, Germany.
The average level of cholesterol in the German adult population is approximately 140 mg/dl. For patients with heart disease, 140 mg/dl is already higher than it should be, and they require treatment, for instance with statins, to bring cholesterol levels down. The higher the patient's risk of heart disease, the lower the LDL cholesterol targets should be. LDL targets are supposed to be less than 100 mg/dl for patients with a history of heart attacks, coronary artery disease, coronary artery bypass grafting, peripheral artery disease, stroke, diabetes, transient ischaemic attacks or a greater than 20% 10-year risk of a heart disease-related event. LDL targets of less than 130 mg/dl apply to patients with two or more vascular risk factors such as diabetes, stroke or peripheral artery disease; and LDL targets of less than 160 mg/dl apply to patients with no, or only one, vascular risk factor and a 10-year risk of heart disease of less then 10%.
Prof Schunkert and his colleagues found that the highest percentage of patients with correctly assigned cholesterol-lowering targets were to be found in the group with LDL targets of less than 100 mg/dl (57.4% correct out of a total of 17,227 patients). Men who had previously suffered heart attacks were the most likely to be assigned a correct target of less than 100 mg/dl (77.1%). For patients assigned a target of less than 130 mg/dl or less than 160 mg/dl, only 41.7% were correct out of a total of 5,551 and 2,472 patients respectively.
Prof Schunkert said: "Our study focused on cholesterol treatment of patients in Germany, and, more specifically, the awareness of primary care physicians for how patients' characteristics affect LDL target values. Even though confined to one nation, the study may highlight similar scenarios in other European countries and those around the world. In fact, similar data were reported from Italy. The core question involves the perception of patient risk: for example, women are often perceived as having a lower cardiovascular risk compared to their real risk, and this may lead to insufficient treatment. This aspect has also been reported in other regions of the world.
"We hope that the data from our study will remind physicians of the need to observe relevant guidelines to calculate individually every patient's target value, so that they can deliver the best possible care to all their patients."
He said there might be a number of reasons why doctors failed to follow guidelines correctly. "I am afraid to say that women are simply overlooked by their physicians, when it comes to cardiovascular risk. Moreover, not all physicians believe in the concept of risk reduction by LDL modification, although the evidence is overwhelming. Their reasons may be multifactorial: some might be confused by different, changing and frequently updated guidelines and some may simply lack time to spend on their patients in primary care. Physicians may need more assistance in determining the risk of their patients, for instance with nurse practitioners or computer programs calculating the risk from the patients' electronic file notes.
"We believe efforts should be made to make guidelines simpler and easier to understand and follow; instruments to identify high-risk patients more easily should be developed; and special attention should be paid to women and patients without known cardiovascular disease, but with an accumulation of risk factors, since both groups appear frequently to escape the notice of doctors for aggressive cholesterol-lowering treatment."
Speaking on behalf of the European Society of Cardiology, Professor Ian Graham, consultant cardiologist at the Adelaide and Meath Hospital, Dublin, Ireland, who was unconnected with the study, said: "Cholesterol in the blood is a risk factor for heart attack. This interesting study suggests that about one half of German primary care physicians have difficulty in assigning appropriate therapeutic target values for LDL cholesterol in subjects with raised blood cholesterol levels. If the target is not clear, less adequate therapy is likely. The study used American target levels for LDL and the situation may be worse than this because European target values for LDL cholesterol are slightly more stringent than American ones.
"These finding will be of value to the ESC's Prevention Implementation Committee in its efforts to promote guideline knowledge and usage throughout Europe, as well as to all involved in medical education at undergraduate and postgraduate level. In some countries, physician re-imbursement is dependent upon achieving risk factor targets which may also be an incentive."
More information: "Physicians' perception of guideline-recommended low-density lipoprotein target values: characteristics of misclassified patients." European Heart Journal. doi:10.1093/eurheartj/ehq026
-
Most heart attack patients' cholesterol levels did not indicate cardiac risk
Jan 12, 2009 |
not rated yet |
0
-
More patients across the world lowering 'bad' cholesterol
Jun 22, 2009 |
not rated yet |
0
-
Adding ezetimibe to atorvastatin improves lipid control
Oct 27, 2009 |
not rated yet |
0
-
Management strategies for high risk stroke patients poor in a majority of cases: study
Jun 08, 2009 |
not rated yet |
0
-
Combination of very low LDL and normal systolic blood pressure attenuate coronary artery disease
Mar 23, 2009 |
not rated yet |
0
-
Engineers build first sub-10-nm carbon nanotube transistor
Feb 01, 2012 |
4.9 / 5 (30) |
30
-
Something old, something new: Evolution and the structural divergence of duplicate genes
Jan 31, 2012 |
4.6 / 5 (7) |
1
-
The hidden nanoworld of ice crystals: Revealing the dynamic behavior of quasi-liquid layers
Jan 30, 2012 |
5 / 5 (3) |
1
-
Stock market network reveals investor clustering
Jan 27, 2012 |
3.9 / 5 (23) |
8
-
Of microchemistry and molecules: Electronic microfluidic device synthesizes biocompatible probes
Jan 26, 2012 |
5 / 5 (1) |
0
-
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011
- More from Physics Forums - Independent Research
More news stories
Cell biologists describes mechanism by which some people may be more susceptible to colon cancer
An international research team led by cell biologists at the University of California, Riverside has uncovered a new insight into colon cancer, the third leading cause of cancer-related deaths in the United ...
45 minutes ago |
5 / 5 (1) |
0
|
Anyone can learn to be more inventive, cognitive researcher says
There will always be a wild and unpredictable quality to creativity and invention, says Anthony McCaffrey, a cognitive psychology researcher at the University of Massachusetts Amherst, because an "Aha moment" is rare and ...
Medicine & Health / Psychology & Psychiatry
13 minutes ago |
not rated yet |
0
|
FDA outlines path for lower-priced biotech drugs
(AP) -- The Food and Drug Administration is preparing to review the first lower-cost versions of biotech drugs, expensive medications which have never before faced generic competition.
Medicine & Health / Medications
23 minutes ago |
not rated yet |
0
Focus on self-improvement, rather than winning, benefits young athletes
Underserved youth athletes report more life skill and character development when their coaches place greater emphasis on creating caring climates instead of focusing on competition, according to research from ...
Medicine & Health / Psychology & Psychiatry
12 minutes ago |
not rated yet |
0
Army studies: High recurrence of shoulder instability, better arthroscopic repair outcomes
Two studies on shoulder instability in a military population were presented today by U.S. Army sports medicine surgeons at the American Academy of Orthopaedic Surgeons' annual meeting. Findings in one study suggest patients ...
14 minutes ago |
not rated yet |
0
'Dark plasmons' transmit energy
Microscopic channels of gold nanoparticles have the ability to transmit electromagnetic energy that starts as light and propagates via "dark plasmons," according to researchers at Rice University.
New method makes culture of complex tissue possible in any lab
Scientists at the University of California, San Diego have developed a new method for making scaffolds for culturing tissue in three-dimensional arrangements that mimic those in the body. This advance, published online in ...
NASA's TRMM satellite sees Cyclone Jasmine in 3-D
Data from NASA's TRMM satellite was used to create a 3-Dimensional look at Cyclone Jasmine, currently moving through the South Pacific Ocean.
New integrated building model may improve fish farming operations
Today's "locavore" movement with its emphasis on eating more locally-produced food is a natural fit for fruits and vegetables in nearly every region, but few entrepreneurs have dared to apply the concept to ...
FBI file: Steve Jobs was considered for govt post
(AP) -- FBI background interviews of some people who knew Apple co-founder Steve Jobs reveal a man driven by power and alienating some of the people who worked with him.
LinkedIn's 4Q earnings strong, revenue doubles
(AP) -- LinkedIn reported a strong fourth quarter as the online professional-networking service added 14 million members. Its net income and revenue beat Wall Street's expectations.
Mar 10, 2010
Rank: not rated yet